Put Options

15 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$78.36 - $124.66 $1.01 Million - $1.61 Million
12,900 Added 47.43%
40,100 $4.76 Million
Q2 2024

Aug 14, 2024

BUY
$80.36 - $102.87 $265,188 - $339,471
3,300 Added 13.81%
27,200 $2.19 Million
Q1 2024

May 15, 2024

SELL
$88.96 - $112.35 $765,056 - $966,210
-8,600 Reduced 26.46%
23,900 $2.2 Million
Q4 2023

Feb 14, 2024

BUY
$90.91 - $112.75 $1.44 Million - $1.78 Million
15,800 Added 94.61%
32,500 $3.43 Million
Q3 2023

Nov 15, 2023

SELL
$98.5 - $125.08 $699,350 - $888,068
-7,100 Reduced 29.83%
16,700 $1.81 Million
Q2 2023

Aug 23, 2023

BUY
$102.58 - $129.66 $2.44 Million - $3.09 Million
23,800 New
23,800 $2.57 Million
Q4 2022

Feb 14, 2023

SELL
$118.43 - $186.05 $1.01 Million - $1.58 Million
-8,500 Reduced 17.78%
39,300 $5.9 Million
Q3 2022

Nov 14, 2022

SELL
$127.65 - $183.11 $791,430 - $1.14 Million
-6,200 Reduced 11.48%
47,800 $6.39 Million
Q2 2022

Aug 15, 2022

SELL
$123.25 - $186.24 $3.52 Million - $5.33 Million
-28,600 Reduced 34.62%
54,000 $7.67 Million
Q1 2022

May 16, 2022

SELL
$126.25 - $231.85 $10.9 Million - $20.1 Million
-86,500 Reduced 51.15%
82,600 $14.4 Million
Q4 2021

Feb 14, 2022

SELL
$216.64 - $362.52 $2.9 Million - $4.86 Million
-13,400 Reduced 7.34%
169,100 $43.4 Million
Q3 2021

Nov 12, 2021

BUY
$205.93 - $447.23 $14.3 Million - $31.1 Million
69,500 Added 61.5%
182,500 $50.6 Million
Q2 2021

Aug 06, 2021

BUY
$113.32 - $241.49 $5.99 Million - $12.8 Million
52,900 Added 88.02%
113,000 $25.8 Million
Q1 2021

May 14, 2021

BUY
$85.73 - $119.5 $1.85 Million - $2.58 Million
21,600 Added 56.1%
60,100 $6.28 Million
Q4 2020

Feb 12, 2021

BUY
$72.71 - $129.54 $2.8 Million - $4.99 Million
38,500 New
38,500 $3.23 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.4B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.